RayKnowChina Research Map
Shortlist

Fuzhou

900th Hospital of the PLA Joint Logistics Support Force

联勤保障部队第九〇〇医院

Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at 900th Hospital of the PLA Joint Logistics Support Force

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌15 papers led
  4. Stomach cancer胃癌17 papers led
  5. Osteosarcoma骨肉瘤1 paper led
  6. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  7. Ewing sarcoma尤文肉瘤1 paper led
  8. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  9. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  10. Alport syndromeAlport 综合征0 papers led
  11. IgA nephropathyIgA 肾病2 papers led
  12. Osteogenesis imperfecta成骨不全症0 papers led
  13. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  14. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  15. Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 002025

5 hospitals in Fuzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueEBV & screeningInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

5 hospitals in Fuzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-05
    Registry
    NCT05515315

    Age 18 years to 70 years (registered criteria)

    Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryEarly detection & endoscopy
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 15 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 2220232024: 1120242025: 332025

6 hospitals in Fuzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiation oncologyMedical oncology
Papers it led15
  1. Efficacy and Safety Analysis of Triple Therapy (Pabolizumab+Cryoablation+Renvastinib) for Patients with Unresectable Hepatocellular Carcinoma (uHCC).2025Archives of Iranian medicineFree full text
  2. The impacts of physical factors on huge hepatocellular carcinoma treated by transarterial chemoembolization combined with radiotherapy.2025Future oncology (London, England)Free full text
  3. A comparative study of argon plasma coagulation and electrosurgical knife on postoperative complications after curative resection for hepatocellular carcinoma.2025Langenbeck's archives of surgeryFree full text
  4. Microvascular invasion is associated with poor survival in patients with dual-phenotype hepatocellular carcinoma.2024American journal of clinical pathology
  5. Upregulation of lncRNA PTOV1-AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR-505.2023Journal of biochemical and molecular toxicology
  6. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.2023Mediators of inflammationFree full text
  7. Overexpression of chaperonin containing TCP1 subunit 7 has diagnostic and prognostic value for hepatocellular carcinoma.2022AgingFree full text
  8. Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients.2022BMC cancerFree full text
  9. Immune Analysis and Small Molecule Drug Prediction of Hepatocellular Carcinoma Based on Single Sample Gene Set Enrichment Analysis.2022Cell biochemistry and biophysics
  10. Decision curve analysis to identify optimal candidates of liver resection for intermediate-stage hepatocellular carcinoma with hepatitis B cirrhosis: A cohort study.2022MedicineFree full text
  11. Immunotherapy and targeted therapy converted radical surgery in an advanced hepatocellular carcinoma with tumor emboi of portal vein and hepatic vein.2021Asian journal of surgery
  12. Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients.2021BioMed research internationalFree full text
  13. High mRNA Expression of CENPL and Its Significance in Prognosis of Hepatocellular Carcinoma Patients.2021Disease markersFree full text
  14. Risk factors associated with suicide among hepatocellular carcinoma patients: A surveillance, epidemiology, and end results analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyFree full text
  15. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.2021MedicineFree full text
Chinese-language papers (not in the count)3
  1. [Correlation analysis between expression of cytokeratin 19 and clinical pathological characteristics and prognosis of dual-phenotype hepatocellular carcinoma].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Association between HULC gene locus rs7763881 polymorphism and recurrence and metastasis after radical resection in hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Clinical efficacy and prognostic risk factors of salvage liver transplantation, rehepatectomy, and local ablation in the treatment of postoperative recurrence of hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status6
  1. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  2. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Study sitePhase 2Start 2021-03
  3. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  4. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  5. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  6. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 4420232024: 4420242025: 442025

6 hospitals in Fuzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopySurgeryPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led17
  1. Pulley traction in endoscopic submucosal dissection of lesions in the upper two-thirds of the stomach: a retrospective study (with video).2026Surgical endoscopy
  2. Electrochemical immunoassay for gastric cancer biomarker pepsinogen I detection based on PdAgPt/MoS2.2025Biomedical materials (Bristol, England)
  3. Multiple gastric tumors in patients with combined autoimmune and helicobacter pylori-associated gastritis: a case report and literature review.2025Frontiers in immunologyFree full text
  4. Optimal neoadjuvant regimens for locally advanced gastric and gastroesophageal junction cancer: a systematic review and bayesian network meta-analysis.2025World journal of surgical oncologyFree full text
  5. Effect of visceral fat area on prognosis of patients undergoing radical gastrectomy and construction of nomogram.2025World journal of surgical oncologyFree full text
  6. Orthodontic rubber band traction to facilitate endoscopic resection of gastric submucosal tumor.2024Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  7. Preoperative ultrasound-guided dual localization with titanium clips and carbon nanoparticles for predicting the surgical approach and guiding the resection of Siewert type II esophagogastric junction adenocarcinoma.2024Journal of cancer research and clinical oncologyFree full text
  8. Feasibility and efficacy of endoscopy with blue laser imaging for the detection and diagnosis of cardia polyps: A single-center randomized controlled study.2024Journal of digestive diseasesRCT
  9. The value of LCI-based modified Kyoto classification risk scoring system in predicting the risk of early gastric cancer.2024Scandinavian journal of gastroenterology
  10. Magnetic ring-assisted endoscopic submucosal dissection for gastric lesions with submucosal fibrosis: A preliminary study in beagle model.2023Asian journal of surgery
  11. Novel beagle model of gastric local fibrotic target lesions for the evaluation and training of endoscopic techniques.2023BMC gastroenterologyFree full text
  12. Clinical effectiveness of fluorouracil and cisplatin intraperitoneal perfusion combined with intravenous chemotherapy for peritoneal metastasis in gastric cancer.2023European review for medical and pharmacological sciences
  13. GPR176 Is a Biomarker for Predicting Prognosis and Immune Infiltration in Stomach Adenocarcinoma.2023Mediators of inflammationFree full text
  14. Usefulness of the combined orthodontic rubber band and clip method for gastric endoscopic submucosal dissection.2022BMC gastroenterologyFree full text
  15. Analysis of Related Risk Factors and Prognostic Factors of Gastric Cancer with Bone Metastasis: A SEER-Based Study.2022Journal of immunology researchFree full text
  16. Linked color imaging-based endoscopic grading of gastric intestinal metaplasia and histological gastritis staging in the assessment of gastric cancer risk.2022Scandinavian journal of gastroenterology
  17. Gastric intestinal metaplasia assessment between linked color imaging based on endoscopy and pathology.2021Scandinavian journal of gastroenterology
Chinese-language papers (not in the count)2
  1. [Progress in the treatment of early gastric cancer with Laparoscopic and endoscopic cooperative surgery].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Exploration of the clinical application of combined endoscopic and laparoscopic surgery in early gastric cancer: 15 cases].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status5
  1. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09
  2. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  3. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  4. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  5. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

13 hospitals in Fuzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Fuzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Fuzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Fuzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEBV & infection triggers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Fuzhou for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Analysis of variants in complement genes in Han Chinese children with atypical hemolytic uremic syndrome].2017Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Fuzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

4 hospitals in Fuzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led2
  1. Construction and diagnostic efficacy assessment of the urinary exosomal miRNA-mRNA network in children with IgA vasculitis nephritis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  2. Exploring the pathogenesis and treatment of IgA nephropathy based on epigenetics.2023Epigenomics
Chinese-language papers (not in the count)1
  1. [Research progress on predictors of renal injury severity in children with IgA vasculitis].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)1
  1. [Genetic variants of familial hematuria associated genes in three families with hematuria with probands initially diagnosed as IgA nephropathy].2019Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Fuzhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Fuzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Fuzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Chinese-language papers (not in the count)1
  1. [Drug-induced bile duct injury: progress and challenges].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Earlier papers (2016–2020)2
  1. Biallelic mutations in DCDC2 cause neonatal sclerosing cholangitis in a Chinese family.2020Clinics and research in hepatology and gastroenterology
  2. Risk factors for recurrent autoimmune liver diseases after liver transplantation: A meta-analysis.2020Medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

4 hospitals in Fuzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

联勤保障部队第九〇〇医院

900th Hospital of the PLA Joint Logistics Support Force

福州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Fuzhou General Hospital; Fuzhou General Hospital of Nanjing Military Command; Dongfang Hospital; Fuzhou General Hospital of Nanjing Command Zone of PLA; Fuzhou General Hospital (Dongfang Hospital); First Affiliated Hospital of Fuzhou General Hospital; Fuzhou General Hospital of Nanjin Military Area Command; Fuzhou General Hospital of Nanjing Military Command Area

Suggest a correctionDownload the data